Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Sebia is a global leader in specialized in vitro diagnostics, providing instruments and reagents for screening and monitoring diseases in Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathies, Autoimmune and Infectious diseases, and other rare disorders.
Polymedco’s mission is to save lives through early detection of life-threatening diseases like colorectal cancer and cardiac diseases by partnering with healthcare systems, payors, providers, and reference labs to build effective screening and early detection programs.
Meet HORIBA in Chicago at the 2025 ADLM, Booth #328. HORIBA designs, develops and distributes worldwide, in vitro diagnostic systems mainly destined for biological analysis in medical laboratories.
HemoSonics’ Quantra® Hemostasis System is revolutionizing bleeding management with its next-generation whole-blood viscoelastic analyzer.
Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics and tissue diagnostics. Powered by key brands, including Erie Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific,
ARKRAY has a long-standing history with fully automated urine chemistry and sediment analysis. Hundreds of urinalysis systems are placed throughout the USA. The new ARKRAY AUTION Bridge (AUTION Eye AI-4510 + AUTION Max AX-4060) is a fully automated, walk
ARK Diagnostics, Inc. is committed to improving health care through the design, development, manufacture and distribution of in vitro diagnostic (IVD) immunoassays for therapeutic drug monitoring (TDM), urine drug testing (UDT) and other small molecules. Our focus is the production of high quality, convenient, cost-effective products for routine use in research and clinical practice.
June 2025—For a relatively sleepy field of study, heparin-induced thrombocytopenia has produced more than its share of thrills in the past few years. HIT (sometimes called HITT, with the extra “T” denoting thrombosis) gave way to urgent discussions about vaccine-induced immune thrombotic thrombocytopenia, or VITT, at one particularly panicky point in the COVID-19 pandemic. Take another spin of the wheel: “VITT-like” is now primarily used to refer to cases in which patients have received neither heparin nor a vaccine. Even more recently, researchers have identified a new syndrome, referred to as monoclonal gammopathy of thrombotic significance (MGTS). Publications have put this disorder into three groups. “I think this is going to be the biggest thing in the thrombophilia field in a long time,” predicts Anand Padmanabhan, MD, PhD, professor, Mayo Clinic. Unlike HIT and VITT, MGTS is a chronic condition. “It may end up being part of a thrombophilia profile in the coming years.”
June 2025—The Duffy null phenotype, legal matters, and unmet needs in STI testing are three of the topics on offer at the ADLM meeting next month in Chicago.
June 2025—The authors of a recently published study suggest repeating HER2 testing on the excision specimen for the small number of breast cancer biopsies with group two and group four FISH results. The aim of their study was to determine if FISH group two and group four cases change HER2 status after repeated testing on additional specimens.
